Market closed
Marker Therapeutics Inc./$MRKR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Ticker
$MRKR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
5
ISIN
US57055L2060
Website
MRKR Metrics
BasicAdvanced
$12M
-
-$1.34
-
-
Price and volume
Market cap
$12M
52-week high
$2.09
52-week low
$0.95
Average daily volume
42K
Financial strength
Current ratio
6.794
Quick ratio
6.457
Management effectiveness
Return on assets (TTM)
-51.17%
Return on equity (TTM)
-97.30%
Valuation
Price to revenue (TTM)
1.857
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-0.841
Growth
Revenue change (TTM)
71.53%
Earnings per share change (TTM)
109.38%
3-year revenue growth (CAGR)
37.19%
3-year earnings per share growth (CAGR)
-36.23%
MRKR News
AllArticlesVideos
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
GlobeNewsWire·17 hours ago
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference
GlobeNewsWire·2 months ago
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Marker Therapeutics Inc. stock?
Marker Therapeutics Inc. (MRKR) has a market cap of $12M as of May 20, 2025.
What is the P/E ratio for Marker Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Marker Therapeutics Inc. (MRKR) stock is 0 as of May 20, 2025.
Does Marker Therapeutics Inc. stock pay dividends?
No, Marker Therapeutics Inc. (MRKR) stock does not pay dividends to its shareholders as of May 20, 2025.
When is the next Marker Therapeutics Inc. dividend payment date?
Marker Therapeutics Inc. (MRKR) stock does not pay dividends to its shareholders.
What is the beta indicator for Marker Therapeutics Inc.?
Marker Therapeutics Inc. (MRKR) does not currently have a Beta indicator.